AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03307382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpyGlass DS Cholangioscopy
Description: SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
Study NCT03833921 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Abiraterone Acetate
Description: 1000 mg orally daily until disease progression
Study NCT03833921 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone
Description: 5 mg oral low dose prednisone, twice daily
Study NCT03325504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Mesenchymal Stem Cells
Description: Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa
Description: standard release levodopa/carbidopa 100/25 mg (single-dose)
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 15 mg
Description: BIA 9-1067 OPC, Opicapone 15 mg
Study NCT01519284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 30 mg
Description: BIA 9-1067 OPC, Opicapone 30 mg
Study NCT03030911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
Study NCT03030911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
Study NCT03030911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The drug will be administered in both groups
Study NCT03030911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: The drug will be administered in both groups
Study NCT03325504 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous iliac crest graft
Description: Autologous iliac crest grafting
Study NCT03030911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: The device will be used for measurement of basal metabolic rate
Study NCT03030911 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Indirect calorimetry
Description: The device will be used for measurement of basal metabolic rate
Study NCT01884857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate ER Tablets 50 mg
Description: 1\* 50 mg tablet once a day
Study NCT01884857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Succinate ER Tablets 50 mg
Description: 1\* 50 mg tablet once a day
Study NCT01884857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'TOPROL-XL®' ER Tablets 50 mg
Description: 1 \* 50 mg tablet per day
Study NCT01884857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 'TOPROL-XL®' ER Tablets 50 mg
Description: 1 \* 50 mg tablet per day
Study NCT00601796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine Treatment
Description: We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
Study NCT00601796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m\^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
Study NCT00601796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Description: All-trans retinoic acid was given (150/mg/m\^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
Study NCT02106455 — intervention group
Intervention type: DRUG
Intervention: Sodium risedronate
Description: Sodium risedronate tablets
Study NCT01172834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: A manual-driven group Health Coaching intervention. Once a week for 3 months.
Study NCT00005060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere-Cisplatin-5FU
Description: Preoperatively
Study NCT00005060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate surgery
Description: Immediate surgery followed by Taxotere-Cisplatin-5FU
Study NCT01063816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib (ABT-888)
Description: Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
Study NCT01063816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be dosed on Day 1 of each cycle, intravenously.
Study NCT01063816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Dosing on Days 1 and 8 of each Cycle, intravenously.
Study NCT01066195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iressa
Description: iressa 250mg per day every day
Study NCT01066195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alimta
Description: alimta 500mg/m2 every 3 weeks
Study NCT00930605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen alternate with ESHAP regimen
Description: CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
Study NCT00930605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
Study NCT01695850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZRW
Description: Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
Study NCT01695850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
Study NCT01695850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
Study NCT01695850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
Study NCT01695850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
Study NCT00150670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1 and cisplatin
Description: TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
Study NCT00150670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TS-1
Description: TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
Study NCT03117166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
Study NCT03117166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
Study NCT04191291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lunch period length
Description: We are randomly allocating a 10 minute or 20 period of seated lunch time.
Study NCT06287008 — intervention group
Intervention type: PROCEDURE
Intervention: robot-assisted kidney transplantation
Description: The interventional surgery is a robot-assisted kidney transplantation and its efficacy will be measured against that of open kidney transplantation
Study NCT04258163 — intervention group
Intervention type: DRUG
Intervention: Capecitabine
Description: 1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days
Study NCT04258163 — intervention group
Intervention type: DRUG
Intervention: Liposomal doxorubicin
Description: 50 mg/m 2 IV day 1, cycled every 28 days
Study NCT04258163 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine
Description: 800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days
Study NCT04258163 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Description: 500mg IH Days 0, 14, 28, then every 28 days
Study NCT04258163 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: 1mg PO qd
Study NCT04258163 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: 2.5mg PO qd
Study NCT04237324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment one side BLE by NAFL
Description: One side of the patient face underwent treatment using the ResurFX module of M22 (Lumenis Co., Yokneam, Israel) randomly.
Study NCT04237324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment another side BLE by FMR
Description: One side of the patient face underwent treatment using FMR device (INFINI, Lutronic Co., Goyang-si, Korea).
Study NCT03863236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: regular diet
Description: The control group (group 1) will continue their regular diet.
Study NCT03863236 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional support Resource 2.5
Description: The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
Study NCT03052842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16G2 Strip
Description: Antimicrobial Peptide
Study NCT03052842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Strip
Description: Placebo
Study NCT00470652 — intervention group
Intervention type: DEVICE
Intervention: computer-assisted decision support
Description: at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept (Half-Dose)
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept (Full-Dose)
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
Study NCT01456013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard of care for patients at risk of CIN
Study NCT02282267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Iressa 250mg oral daily
Study NCT02285413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination without cisplatinum
Study NCT02285413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination with cisplatinum
Description: DC vaccination with cisplatinum
Study NCT00130156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bunazosin
Description: Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
Study NCT00130156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulfasalazine
Description: AS patients who satisfied the criteria for disease remission (ASDAS\<1.3) will take sulfasalazine (2g/d) from week12 to week48.
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib (0.4g/d) will be the background therapy.
Study NCT01769274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
Study NCT01769274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
Study NCT02749292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: re-dosing dependent on interventional arm parameter.
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib (0.4g/d) will be the background therapy.
Study NCT00534794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elestat
Description: Elestat BID for 2 days
Study NCT00534794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pataday
Description: Pataday QD for 2 days
Study NCT04325152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FCSEMS plus Clip
Description: After successful cannulation, a 10mm FCSEMS with the length of 6cm or 8cm were inserted into CBD. Then a metal clip was used to fix the distal end of FCSEMS with the duodenal mucosa adjacent to papilla.
Study NCT04325152 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FCSEMS
Description: FCSEMS was released as the same as mentioned above. No fixating method was used.
Study NCT02182128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Study NCT01770431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
Study NCT00512837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile phone technology
Study NCT04334655 — intervention group
Intervention type: OTHER
Intervention: Physical Therapy
Description: Patients with primary complaints of neck pain will receive routine physical therapy care including modalities, manual therapy including neck mobilization and manipulation, stretching and strengthening exercises, and patient education.
Study NCT00839059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days
Study NCT04513808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol-based total intravenous anesthesia
Description: Propofol-based total intravenous anesthesia, titrated to clinical need.
Study NCT04513808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane intravenous anesthesia
Description: Sevoflurane intravenous anesthesia, titrated to clinical need.
Study NCT02457338 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium
Study NCT02096211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: COC 36mm
Description: Total Hip Replacement with COC 36mm Acetabular Cup System
Study NCT04483778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ B7H3-EGFRt-DHFR
Description: Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR
Study NCT04483778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Description: Autologous CD4+ and CD8+ T-cells lentivirally transduced to express a second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
Study NCT01095055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMA1
Description: Group 1A - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly
Study NCT01095055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 AMa1 and MVA AMA1
Description: Group 1B - single dose of AdCH63 AMA1 5x10\^9 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10\^10 vp intramuscularly and single dose of MVA AMA1 5x10\^8 pfu 8 weeks later intramuscularly
Study NCT00130156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartin
Description: After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
Study NCT02273544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation - low)
Study NCT02273544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation - medium)
Study NCT02638896 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Celecoxib
Description: Celecoxib (0.4g/d) will be the background therapy.
Study NCT00377611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Study NCT01728753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
Study NCT01728753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1200 mg TID on Day 1, then 600 mg TID on Days 2-5
Study NCT02273544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER (new formulation - high)
Study NCT02273544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER - commercial formulation
Study NCT03586258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests
Study NCT03586258 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuropsychological testing
Description: Experimental test about cognitive deficit of interest and standard neuropsychological tests
Study NCT03586258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Imaging
Description: Anatomical, diffusion, and/or functional MRI
Study NCT03586258 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Imaging
Description: Anatomical, diffusion, and/or functional MRI
Study NCT03586258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation (GVS)
Description: Stimulation versus Sham
Study NCT03586258 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Galvanic Vestibular Stimulation (GVS)
Description: Stimulation versus Sham